Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sintx Technologies Inc (GB:0A8S)
LSE:0A8S
RESEARCH TOOLSreports
Sintx Technologies (0A8S) Share Price & Analysis
0 Followers
0A8S Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.02 - $1.69
Previous Close$0.04
Volume321.10K
Average Volume (3M)139.48K
Market Cap
$4.39M
Enterprise Value$5.30M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$4.25M
Price to Earnings (P/E)N/A
Beta1.13
Next Earnings
Mar 28, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,680,139
10 Day Avg. Volume311
30 Day Avg. Volume139,476
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.10
Price to Sales (P/S)72.84
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.22
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda-2.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Sintx Technologies News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthSINT preannounced 4Q23 revenue of $0.9M, up 17.8% y/y, indicating growth in sales.
New ContractSINT announced a new aerospace advanced ceramics contract expected to generate approximately $800,000/year in revenue.
Revenue ForecastSINT preannounced 4Q23 revenue of $0.9M, above the prior $0.6M forecast, leading to an increased 2023 revenue estimate to $2.6M.
Bears Say
Capital StructureRecent equity offering at $0.25 per common share was more dilutive than previously anticipated.
Financial PerformanceSINT's EBITDA loss for 2023 was wider than the previous year, reflecting increased operational costs.
Stock ValuationAnalyst maintains a Hold rating on the stock due to capital needs and significant dilution concerns.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.66%
Insiders
0.05% Mutual Funds
0.04% Other Institutional Investors
99.25% Public Companies and
Individual Investors
0A8S FAQ
What was Sintx Technologies Inc’s price range in the past 12 months?
Sintx Technologies Inc lowest share price was $0.02 and its highest was $1.69 in the past 12 months.
What is Sintx Technologies Inc’s market cap?
Currently, no data Available
When is Sintx Technologies Inc’s upcoming earnings report date?
Sintx Technologies Inc’s upcoming earnings report date is Mar 28, 2024 which is 30 days ago.
How were Sintx Technologies Inc’s earnings last quarter?
Sintx Technologies Inc released its earnings results on Mar 30, 2023. The company reported -$17.53 earnings per share for the quarter, missing the consensus estimate of -$6.02 by -$11.51.
Is Sintx Technologies Inc overvalued?
According to Wall Street analysts Sintx Technologies Inc’s price is currently Overvalued.
Does Sintx Technologies Inc pay dividends?
Sintx Technologies Inc does not currently pay dividends.
What is Sintx Technologies Inc’s EPS estimate?
Sintx Technologies Inc’s EPS estimate is -$0.44.
How many shares outstanding does Sintx Technologies Inc have?
Sintx Technologies Inc has 122,680,140 shares outstanding.
What happened to Sintx Technologies Inc’s price movement after its last earnings report?
Sintx Technologies Inc reported an EPS of -$17.53 in its last earnings report, missing expectations of -$6.02. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sintx Technologies Inc?
Among the largest hedge funds holding Sintx Technologies Inc’s share is Gilder Gagnon Howe & Co LLC.. It holds Sintx Technologies Inc’s shares valued at N/A.
---
Sintx Technologies Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.77%
12-Months-Change
Fundamentals
Return on Equity
-114.11%
Trailing 12-Months
Asset Growth
-2.59%
Trailing 12-Months
Company Description
Sintx Technologies Inc
SINTX Technologies, Inc. operates as a commercial biomaterial company. It focuses on using silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The firm markets spinal fusion products and develops products for use in total hip and knee joint replacements. Its FDA-cleared and CE-marked spine products are marketed in the U.S. and selected markets in Europe and South America. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.
---
0A8S Stock 12 Months Forecast
Average Price Target
―Technical Analysis
BioNano Genomics
―
Sintx Technologies
―
Acasti Pharma
―
Iterum Therapeutics
―
CytoDyn
―
Best Analysts Covering 0A8S
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+29.58%
reiterated a buy rating 9 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +29.58% per trade.
---